qtr). GSK assigned the product development and commercialization agreement (PDC Agreement) between GSK and Pozen (NASDAQ: POZN ) to Pernix. Updated 2014 guidance : revenue: $110M - 120M; non-GAAP EBITDA: $22M - 24M. 2015 guidance
Pozen , Inc. (NASDAQ: POZN ) Q2 2014 Earnings Conference Call August 7, 2014 ..... Operator Greetings and welcome to the POZEN Incorporated second quarter 2014 earnings ..... you, and good morning. On behalf of POZEN , I would like to welcome everyone to
Pozen ( POZN +0.5% ) Q2 results : Revenues: $7.4M (+335.3%); Operating Expenses: $4.4M (-21.7%); Net Income: $3.0M (+175.2%); EPS: $0.09 (+169.2%); Quick Assets: $31.8M (-3.0%). No guidance given. Post your comment!
The following audio is from a conference call that will begin on August 07, 2014 at 11:00 AM ET. The audio will stream live while the call is active, and can be replayed upon its completion. Listen now Complete Story »
By Jason Napodano : On July 28, 2014, Horizon Pharma, Inc. (NASDAQ: HZNP ) filed a Form 8-K with the SEC disclosing that two pharmacy benefit managers, CVS Caremark (NYSE: CVS ) and Express Scripts, Inc. (NASDAQ: ESRX ), expect to announce DUEXIS® and VIMOVO® will no longer be on their formularies
12% . IMMY +9% . GLMD +9% . MOVE +8% . PCO +8% . Top 10 Losers: ACRX -41% . HZNP -34% . EDAP -27% . SMLR -20% . POZN -15% . LOAN -15% . CRNT -14% . VBFC -13% . PTX -11% . OTCQB:AMTX -10% . Post your comment!
Shares of Pozen ( POZN -14.4% ) get smacked down on a 2x surge in volume in sympathy with Horizon Pharma's ( HZNP -33.2% ) bad news . Pozen earns a 10% royalty on Vimovo sales. Post your comment!
Gainers: TWX +16% . IGT +9% . NEWL +9% . ISR +6% . PT +5% . FEYE +5% . INTC +5% . Losers: BIOA -16% . POZN -6% . 1 comment!
The FDA accepts Pozen 's (NASDAQ: POZN ) resubmission of its NDA for PA8140/PA32540 and sets a PDUFA ..... decreases the risk of developing aspirin-associated gastric ulcers. POZN shares are down 6% premarket on modest volume. Post your comment
resembling a consensus on best practices for money funds. For example, earlier this week two former fund executives, Robert Pozen and Terry Hamacher, penned an Opinion article in The Wall Street Journal that stated support for the first of the SEC's two